Monday, September 14, 2026
← Back to archivePolicy
Policy•STAT News•Sep 14, 2026
Opinion: Am I a hypocrite for loving football despite CTE?
background ▾
- •This article does not contain pharma/biotech industry news and is unsuitable for pharmaceutical professional analysis
Policy•STAT News•Sep 14, 2026
Opinion: Restoring public trust in science doesn’t have a simple solution. That’s OK
background ▾
- •Trust in science is a complex problem rooted in institutional and expertise credibility issues that cannot be solved by communication alone—it requires genuine community partnership and bidirectional engagement
Policy•STAT News•Sep 14, 2026
The GOP’s $50 billion rural health fund is coming up short, hospital leaders say
background ▾
- •The $50 billion rural health fund transformed from intended direct financial support for hospitals facing Medicaid cuts into a program-based innovation fund focused on workforce, technology, and chronic disease management, leaving hospital leaders significantly disappointed.
- •Rural hospital leaders are reconsidering participation in the fund, concerned they lack capital to sustain programs built with temporary funding, especially as they brace for reduced government reimbursement.
- •The disconnect between hospital financial crisis and fund priorities highlights ongoing tension between policymakers' innovation agenda and rural providers' immediate operational sustainability needs—watch for participation rates and whether fund structures adapt to address provider concerns.
Northern Light HealthLifeFlight of MaineMDI Health
→ Read original articlePolicy•Fierce Biotech•Sep 11, 2026
FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
background ▾
- •FDA requested updated safety and efficacy data, delaying zanzalintinib-Tecentriq approval from December 2026 to March 2027—the specific rationale for this request remains unclear and could signal regulatory concern beyond the missed subgroup endpoint
- •The drug missed a primary endpoint in the liver metastases subpopulation but succeeded in the overall population and in head-to-head comparison with Stivarga, creating ambiguity about approvability and potential label restrictions
- •Monitor March 2027 FDA decision and readouts from parallel phase 3 trials (Stellar-311 in neuroendocrine tumors and Stellar-304 in non-clear cell RCC expected H2 2024) to assess zanzalintinib's broader pipeline momentum
ExelixisRocheBayerzanzalintinibTecentriqatezolizumab
→ Read original articlePolicy•Fierce Biotech•Sep 11, 2026
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
background ▾
- •Andy Plump departing Takeda R&D after 12 years signals leadership transition at a time when the company faces revenue pressure from Vyvanse exclusivity losses, though his replacement and timing remain uncertain
TakedaSofinnova InvestmentsPyxis OncologyVyvanseOrzeyfulMimrylo
→ Read original articleMarket Access
Market Access•Fierce Biotech•Sep 11, 2026
Singapore launches biotech-focused Boston hub to build on 'centuries-old bond'
background ▾
- •Singapore established a biotech-focused hub in Boston to bridge its emerging life sciences sector with U.S. venture capital, corporations, and regulatory expertise.
- •This represents Singapore's first state-level economic partnership agreement in the U.S., signaling government commitment to deepening Boston-Singapore biotech ties.
Enterprise SingaporePolaris PartnersMPM BioImpact
→ Read original articleMarket Access•Fierce Biotech•Sep 13, 2026
GE HealthCare mulls $1B imaging chemicals maker deal: Financial Times
background ▾
- •GE HealthCare seeks to vertically integrate radiopharmaceutical chemistry with its imaging hardware platform through potential $1B acquisition of Sofie Biosciences
- •Transaction reflects strategic shift toward end-to-end imaging solutions following GE's April 2024 restructuring and creation of Advanced Imaging Solutions segment
- •Monitor for official announcement and integration details, particularly regarding Sofie's oncology-focused radiopharmaceutical pipeline and GE's go-to-market strategy
GE HealthCareSofie Biosciences
→ Read original articleMarket Access•Fierce Biotech•Sep 11, 2026
The future of RAS inhibitors
background ▾
- •Rasonque's pancreatic cancer approval validates RAS inhibitors as a significant new therapeutic class and opens multiple expansion opportunities beyond KRAS G12C lung cancer
- •Verastem and other rivals are actively developing next-generation RAS-targeting approaches, suggesting intense competition will shape this market segment going forward
- •Commercial success and real-world penetration remain uncertain; monitoring ASCO/AACR presentations and upcoming label expansions will be critical to assessing the RAS inhibitor market trajectory
Revolution MedicinesVerastem OncologyRasonquesotorasib
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 14, 2026
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
background ▾
- •Zipalertinib + chemotherapy achieved 14.5-month median PFS versus 8.5 months for chemotherapy alone in treatment-naïve EGFR exon 20 insertion-mutant NSCLC, a clinically significant 6-month improvement with favorable tolerability
- •Immature OS data show a hazard ratio of 0.72 (28% mortality risk reduction), suggesting potential for a meaningful survival advantage pending maturation
- •Monitor for mature OS readout and regulatory pathway; competitive positioning against Rybrevant (J&J) and other exon 20-targeted agents will depend on final safety/efficacy profile and regulatory approval timeline
Cullinan TherapeuticsTaiho OncologyJohnson & JohnsonzipalertinibRybrevantTagrisso
→ Read original articleClinical Trials•Fierce Biotech•Sep 12, 2026
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
background ▾
- •Ris-rez achieved 18.5-month median OS in second-line SCLC, substantially outperforming topotecan (10.3 months) and comparing favorably to Amgen's Imdelltra and Merck/Daiichi's I-DXd in head-to-head efficacy.
- •No grade 4/5 interstitial lung disease events in the Hansoh trial versus fatal ILD/pneumonitis in competitor trials suggests a potential safety differentiation that could strengthen competitive positioning.
- •China-only trial enrollment raises questions about translating efficacy to global populations; GSK expects global phase 3 data in 2027, putting it behind rivals but allowing parallel data generation to inform strategy.
GSKHansoh PharmaMerckrisvutatug rezetecanImdelltraifinatamab deruxtecan
→ Read original articleClinical Trials•Fierce Biotech•Sep 14, 2026
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
background ▾
- •Gotistobart demonstrated 18.5-month median OS versus 10 months docetaxel in relapsed sqNSCLC—a magnitude of survival benefit substantially exceeding multiple prior failed competitors (Trodelvy 11.1mo, Datroway 12.9mo, Cabometyx+Tecentriq 10.7mo)
- •Serious adverse event rate of 44.4% on gotistobart versus 29.3% on docetaxel, with colitis predominating, presents a significant safety/tolerability liability that could limit adoption despite efficacy gains
- •Pivotal stage interim analysis expected end of 2024—confirmation of OS benefit is critical to regulatory approval path; failure to replicate would substantially diminish gotistobart's near-term commercial prospects
BioNTechGileadAstraZenecagotistobartdocetaxelramucirumab
→ Read original articleClinical Trials•Fierce Biotech•Sep 11, 2026
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
background ▾
- •INTerpath-001 phase 3 trial met primary endpoint with statistically significant and clinically meaningful improvement in recurrence-free survival for intismeran + Keytruda versus Keytruda alone in adjuvant melanoma setting
- •Full detailed data remain withheld pending presentation at future medical conference, limiting ability to assess clinical magnitude and compare to historical controls
- •Watch for: complete trial readout, regulatory submissions (likely BLA/MAA), expansion into other cancer indications, and whether this catalyzes approvals in competing mRNA personalized cancer vaccine programs
Merck & Co.ModernaArcturus Therapeuticsintismeran autogeneV940mRNA-4157
→ Read original articleClinical Trials•Endpoints News•Sep 13, 2026
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
background ▾
- •PD-1×VEGF bispecific antibody shows overall survival advantage versus Keytruda in head-to-head comparison, validating dual-targeting immuno-oncology strategy
- •Clinical success positions Akeso/Summit for potential accelerated development and competitive positioning in checkpoint inhibitor-resistant or difficult-to-treat tumor segments
- •Watch for full trial data presentation at major oncology conferences and regulatory strategy announcements (breakthrough designation potential, accelerated approval path)
AkesoSummit TherapeuticsMerckPD-1×VEGF bispecific antibodyKeytrudapembrolizumab
→ Read original article